Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.40 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9298515 | 1.00 | BRD4 (0.45) | BRD4HDAC4HDAC7HDAC5CYP2C9 | |
| SCHEMBL17633670 | 0.82 | CYP1A2 (0.45) | MEN1CYP2C19KMT2ACES2CES1 | |
| SCHEMBL5742269 | 0.82 | CES2 (0.46) | BRD4HDAC4HDAC7HDAC5CYP2C9 | |
| SCHEMBL75753 | 0.82 | CES2 (0.52) | BRD4HDAC4HDAC7HDAC5CYP2C9 | |
| SCHEMBL9298853 | 0.82 | CES2 (0.52) | BRD4HDAC4HDAC7HDAC5CYP2C9 | |
| Hydrochloric Acid SCHEMBL75859 | 0.80 | CES2 (0.50) | BRD4HDAC4HDAC7HDAC5CYP2C9 | |
| SCHEMBL622334 | 0.80 | BRD4 (0.59) | BRD4HDAC4HDAC7HDAC5CYP2C9 | |
| SCHEMBL7473524 | 0.80 | CYP2C9 (0.44) | BRD4HDAC4HDAC7HDAC5CYP2C9 | |
| SCHEMBL9558033 | 0.80 | HDAC3 (0.44) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL9285788 | 0.80 | ALDH1A1 (0.43) | MEN1KMT2ACES2CES1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160122283-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| US-20160122283-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| US-20160122283-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| US-9321716-B1 | Compositions and methods for the treatment of metabolic syndrome | CELLIX BIO PRIVATE LIMITED (IN) | 2016-04-26 | — | — | US | disclosed |
| US-9321716-B1 | Compositions and methods for the treatment of metabolic syndrome | CELLIX BIO PRIVATE LIMITED (IN) | 2016-04-26 | — | — | US | disclosed |
| US-9321716-B1 | Compositions and methods for the treatment of metabolic syndrome | CELLIX BIO PRIVATE LIMITED (IN) | 2016-04-26 | — | — | US | disclosed |
| EP-1919857-B1 | PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF | SYNGENTA PARTICIPATIONS AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| EP-1919857-B1 | PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF | SYNGENTA PARTICIPATIONS AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| CN-101243040-B | Synthesis method of mandipropamid and derivatives thereof | SYNGENTA PARTICIPATIONS AG | 2012-12-05 | — | — | CN | disclosed |
| US-8129560-B2 | Process for the synthesis of mandipropamid and derivatives thereof | SYNGENTA CROP PROTECTION, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| WO-2007020381-A2 | PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF | SYNGENTA PARTICIPATIONS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007020381-A2 | PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF | SYNGENTA PARTICIPATIONS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| EP-0441539-B1 | Thiazine (or oxazine) derivatives and preparation thereof | TANABE SEIYAKU CO (JP) | 1996-04-10 | — | — | EP | disclosed |
| US-5496815-A | TREATMENT OF ISCHEMIC ENCEPHALOPATHIA | TANABE SEIYAKU CO., LTD. (JP) | 1996-03-05 | — | — | US | disclosed |
| US-5374656-A | Nervous system disorders, gastrointestinal disorders | RHONE-POULENC RORER, S.A. (FR) | 1994-12-20 | — | — | US | disclosed |
| US-5281592-A | Calcium antagonist, antiischemic agents, brains, nervous system disorders | TANABE SEIYAKU CO., LTD. (JP) | 1994-01-25 | — | — | US | disclosed |
| US-5246929-A | Prophylaxis or treatment of ischemic encephalopathia | TANABE SEIYAKU CO., LTD. (JP) | 1993-09-21 | — | — | US | disclosed |
| EP-0441539-A2 | Thiazine (or oxazine) derivatives and preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 1991-08-14 | — | — | EP | disclosed |
| US-4639541-A | FUNGICIDES | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 1987-01-27 | — | — | US | disclosed |
| US-3971828-A | METABOLISM, PROPHYLAXIS | SANTEN PHARMACEUTICAL CO. LTD. (JA) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122283-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | SLC5A1, SLC5A2, SLC2A1 | BRD4 4598/4885HDAC4 3320/4885HDAC7 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.